117 results about "Immune effector cell" patented technology

Provided herein are chimeric antigen receptors (CARs) for cancer therapy, and more particularly, CARs containing a scFv from an anti-ROR-1 monoclonal antibody. Provided are immune effector cells containing such CARs, and methods of treating proliferative disorders.

The present disclosure features modified immune effector cells (e.g., T cells or NK cells) having increased resistance to inhibition of an immunosuppressive agent relative to unmodified immune effector cells, compositions comprising the same, and methods of using the same.

Provided herein are chimeric antigen receptors (CARs) for cancer therapy, and more particularly, CARs containing a scFv from a CD33 monoclonal antibody. Provided are immune effector cells containing such CARs, and methods of treating proliferative disorders such as acute myeloid leukemia (AML), and relapsed or refractory AML.

Provided are anti-Claudin-6 antibodies (e.g., VHH domain antibodies), and a chimeric antigen receptor (CAR) that binds to Claudin-6 comprising same in an extracellular antigen binding domain, a transmembrane domain, and an intracellular signaling domain. Immune effector cells transduced with the disclosed CAR constructs can be used for cancer immunotherapy.

The invention relates to a CD19 and CD70 targeted double-target chimeric antigen receptor and application thereof, the CD19 and CD70 targeted double-target chimeric antigen receptor comprises an extracellular antigen binding domain, a hinge region, a transmembrane domain, an intracellular costimulatory domain and an intracellular signal transduction domain, and the extracellular antigen binding domain has specific binding ability to CD19 and CD70. The double-target chimeric antigen receptor structure has a treatment effect of targeting double antigens or single antigens, can be used for preparing immune effector cells targeting CD19 and CD70, and provides a treatment or improvement approach for diseases related to CD19 and CD70 double expression or CD19 / CD70 single expression.

Disclosed are methods and compositions related to chimeric antigen receptors (CARs) that recognize Tissue Factor (TF). Specifically, disclosed are CARs that comprise fVII or a functional fragment thereof. Also disclosed are immune effector cells comprising the CARs disclosed herein.

The present disclosure pertains to methods of making immune effector cells (for example, T cells or NK cells) that express a chimeric antigen receptor (CAR), and compositions generated by such methods. Also disclosed herein are methods of using such compositions for treating a disease, for example, cancer, in a subject.

The invention provides an antibody specifically binding to CLL-1 or an antigen binding fragment thereof, a multispecific antigen binding molecule, a chimeric antigen receptor, an immune effector cell, a nucleic acid fragment, a carrier, a host cell, a pharmaceutical composition, a kit, a preparation method and application thereof in disease treatment and CLL-1 detection.

This application provides a BCMA-targeting chimeric antigen receptor (CAR) comprising a BCMA-binding domain and an intracellular costimulatory domain derived from DAP10. Also provided are engineered immune effector cells (e.g., NK cells) containing the chimeric antigen receptor. Pharmaceutical compositions, kits, and methods for treating cancer are also provided.

The present invention relates to the field of biotechnology and immunooncology. The invention discloses a bispecific antibody. The bispecific antibody comprises an antibody, an antibody fragment or a single-chain variable fragment for recognizing NGcGM3 ganglioside on tumor cells and an antibody, an antibody fragment or a single-chain variable fragment for recognizing a CD3 antigen on human immune effector cells. These bispecific antibodies are characterized in that they are capable of mediating selective cytotoxicity against NGcGM3-positive tumor cells, rather than normal cells capable of expressing the gangliosides, and allow recruitment of not only T lymphocytes but also NKT. The bispecific antibodies of the invention, as well as the nucleic acids encoding them, are useful for the treatment of lymphoproliferative diseases and solid tumors expressing NGcGM3.

The present invention provides anti-claudin 18.2 nanobodies or their binding fragments. The antibody exhibits good specificity, and immune effector cells targeting claudin 18.2 prepared using the antibody show good therapeutic efficacy in treating or improving diseases with positive claudin 18.2 expression.

The invention provides a system that comprises pharmaceutical agents for use in immunotherapy for reducing the side-effects of an antigen-recognizing receptor against antigen-expressing non-target cells in an individual. The system includes an antigen-recognizing receptor that specifically recognizes an antigen on target cells and at least on one hematopoietic cell type in the individual. The antigen-recognizing receptor is exemplified by chimeric antigen receptors (CAR) be expressed on the surface of an immune effector cells. The system also includes hematopoietic cells resistant to recognition of the same antigen by the antigen-recognizing receptor.

Provided are therapies comprising immune effector cells, such as T cells, engineered to express an antigen receptor, such as a T cell receptor or a chimeric antigen receptor.SOLUTION: It is demonstrated that antigen receptor-engineered immune effector cells can be generated in vitro / ex vivo as well as in vitro by delivering a nucleic acid encoding an antigen receptor for genetic modification to a cell using a particle comprising the nucleic acid and a targeting molecule for targeting the immune effector cell, wherein the targeting molecule is a designed ankyrin repeat protein (DARPin). In particular, DARPins are provided that are high affinity binders for CD8 binding to CD8 receptors on human and non-human primate (NHP) cells. Nanoparticles functionalized with CD8 targeting DARPins (CD8 - DARPins) can deliver genes exclusively and specifically to human CD8 + T cells in vitro and in vivo.SELECTED DRAWING: None

Provided are a TL1A single-domain antibody and the use thereof. Specifically provided are a single-domain antibody or antigen-binding fragment specifically binding to human TL1A, a multispecific antigen-binding molecule, a chimeric antigen receptor, an immune effector cell, a nucleic acid molecule, a vector, a cell, a preparation method, a pharmaceutical composition, a kit, a pharmaceutical use, and a disease treatment method.

The present invention relates to a bispecific antibody construct comprising (a) a first binding domain (A), which is capable of specifically binding to a first target (A′) that is CD16A on the surface of an immune effector cell, wherein the first binding domain comprises: (i) a VL region comprising CDR-L1 as depicted in SEQ ID NO: 4, a CDR-L2 as depicted in SEQ ID NO: 5, and a CDR-L3 as depicted in SEQ ID NO: 6; and (ii) a VH region as depicted in SEQ ID NO: 7 or SEQ ID NO: 134; and (b) a second binding domain (B), which is capable of specifically binding to a second target (B′) that is an antigen on the surface of a target cell. The present invention also relates to related nucleic acid molecules, vectors, host cells, methods of producing the antibody constructs, pharmaceutical compositions, medical uses, and kits.

A method for treating a tumor, characterized by administering to an individual having a tumor immune effector cells expressing a receptor recognizing a tumor antigen and gemcitabine. A kit for treating a tumor, characterized by comprising: 1) immune effector cells expressing a receptor recognizing a tumor antigen; 2) gemcitabine; 3) a container for containing the above 1) and 2); and 4) a written notice for treating a tumor using the kit.

The invention relates to variants of the alpha subunit of interleukin-2 receptor (IL2R) and interleukin-2 (IL2). In one embodiment, the IL2 variants described herein have amino acid substitutions at the region of IL2 that contacts the alpha (α) subunit of the heterotrimeric IL2 receptor complex, IL2Rαβγ, reducing its ability to bind and activate the heterotrimeric receptor complex. Conversely, the corresponding IL2Rα variants described herein have amino acid substitutions compensating for such reduced ability of IL2 variants to bind to and activate IL2Rαβγ, preferably at amino acid residues contacted by IL2 amino acid residues that are substituted in the IL2 variants described herein.

The present disclosure provides compositions and methods comprising recombinant particles suitable for specifically delivering one or more chimeric antigen receptors to immune effector cells in vivo.

A method for treating a tumor, characterized by administering to an individual having a tumor immune effector cells expressing a receptor recognizing a tumor antigen and gemcitabine. A kit for treating a tumor, characterized by comprising: 1) immune effector cells expressing a receptor recognizing a tumor antigen; 2) gemcitabine; 3) a container for containing the above 1) and 2); and 4) a written notice for treating a tumor using the kit.

The present disclosure provides a method for rapid production of genetically modified immune effector cells, such as T cells, from a mixed mononuclear cell population. The method includes activating a T cell population contained in the mixed mononuclear cell population, and, following a post-activation period of up to three hours, exposing the mixed mononuclear cells containing the activated T cell population to at least one viral vector employed to transduce at least the T cell population contained in the mixed mononuclear cell population with an exogenous nucleotide. The method allows for rapid production of genetically modified immune effector cells, such as CAR T cells.

The present application relates to a genetically modified immune cell for expressing a recombinant human CD16 protein. The recombinant human CD16 protein has additions, deletions and replacements of, or any combination of the additions, deletions and replacements of one or more amino acids as compared to a wild-type amino acid sequence, and has enhanced shear resistance.

The invention relates to a CD70 and BCMA targeting dual-targeting chimeric antigen receptor and an application thereof. The CD70 and BCMA targeting dual-targeting chimeric antigen receptor has specific binding ability to CD70 and BCMA. The immune effector cell prepared on the basis of the double-targeting chimeric antigen receptor has the following advantages that the probability that tumor cells escape treatment by losing a single antigen is greatly reduced, and the targeting treatment effect is improved; a CD70 nano antibody sequence is used, so that the length of an insertion fragment is greatly shortened, and the development difficulty of a process end is reduced; and the polypeptide has excellent proliferation capacity, is beneficial to prolonging the in-vivo duration time, and plays a more remarkable anti-tumor role. The invention provides a treatment or improvement approach for diseases related to BCMA-CD70 expression.

The invention provides methods of making immune effector cells (for example, T cells, NK cells) that express a chimeric antigen receptor (CAR), and compositions generated by such methods, and therapeutic uses thereof for treating autoimmune diseases or disorders.

The present application discloses immune effector cells expressing extracellular PD-L1 binding domain CAR and linking secretory interferon fusion protein and application methods thereof. The protein construct involved in the immune effector cells includes: (a) a chimeric antigen receptor (CAR) containing a PD-L1 binding domain; and (b) a secretory fusion protein containing IFN. The protein construct stimulates tumor cells to increase the expression amount or frequency of PD-L1, thereby further enhancing the killing ability of PD1-CAR-T cells on target cells and more effectively inhibiting or killing tumor cells.

The present application relates to signal conversion receptors, and specifically provides a signal conversion receptor comprising an extracellular region, a transmembrane region and an intracellular region, wherein the intracellular region comprises a CD25 intracellular domain, and optionally further comprises an intracellular domain of a costimulatory signaling molecule. An immune effector cell expressing the signal conversion receptor has a higher positive rate, activation level and target cell killing ability compared with a control cell.

Provided herein are methods, compositions, and kits for treating tumors by combining patient-derived immune effector cells with cytokine and therapeutic agents. In one aspect, apheresis material is processed to isolate at least two products selected from T cell, NK cell, and dendritic cell populations, which are formulated and administered to the patient. In another aspect, invariant natural killer T (iNKT) cells are expanded ex vivo using an IL-15:IL-15Rα complex and α-galactosylceramide delivered on a bacterial minicell nanoparticle, enabling scalable production of functional cells. Additional embodiments include tumor microenvironment preconditioning regimens and use of IL-15 superagonists to convert "cold" tumors into "hot" tumors.

To provide anti- CD3 antibodies that more closely mimic TCR / MHC interactions and are desirable for minimizing the release of toxic cytokines while maintaining effective tumor cytolysis.SOLUTION: Novel human CD3 antigen binding polypeptides and their preparation and their use in the treatment and / or diagnosis of various diseases, as well as bispecific antibody molecules capable of activating immune effector cells and their use in the diagnosis and / or treatment of various diseases. In some embodiments, the anti-CD3 antibody is characterized or selected to have a reduced tendency to induce cytokine release upon binding to a competent T cell, e.g., due to the release of IL-2 and IFN γ.SELECTED DRAWING: Figure 1

Described herein are methods of preventing or treating cytokine release syndrome and / or immune effector cell associated neurotoxicity syndrome (ICANS).

To provide a method and composition for generating induced non-pluripotent cells differentiated from single-cell induced iPSC (induced pluripotent stem cell) clone lines. [Solution] A method and composition are provided for obtaining functionally enhanced induced effector cells obtained from targeted differentiation of genome-manipulated iPSCs. The iPSC-induced cells provided herein have stable functional genome editing that results in improved or enhanced therapeutic effects. Therapeutic compositions and their use are also provided, comprising functionally enhanced induced effector cells alone or in combination therapy with antibodies or checkpoint inhibitors.